Cargando…

Aspirin has a better effect on PIK3CA mutant colorectal cancer cells by PI3K/Akt/Raptor pathway

BACKGROUND: Aspirin, as a non-steroidal anti-inflammatory drug, can improve the survival rate of patients with colorectal cancer, while aspirin is effective in patients with PIK3CA mutant colorectal cancer (CRC). However, the mechanism of aspirin in the treatment of PIK3CA mutated CRC patients remai...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Zhihang, Wang, Chun, Dong, Hao, Wang, Xing, Gao, Feng, Zhang, Sen, Zhang, Xiaolong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6993447/ https://www.ncbi.nlm.nih.gov/pubmed/32000660 http://dx.doi.org/10.1186/s10020-020-0139-5

Ejemplares similares

Aspirin exerts high anti-cancer activity in PIK3CA-mutant colon cancer cells
por: Gu, Mancang, et al.
Publicado: (2017)

The effect of rapamycin, NVP-BEZ235, aspirin, and metformin on PI3K/AKT/mTOR signaling pathway of PIK3CA-related overgrowth spectrum (PROS)
por: Suzuki, Yasuyo, et al.
Publicado: (2017)

Targeting glutamine metabolism in PIK3CA mutant colorectal cancers
por: Feng, Xiujing, et al.
Publicado: (2016)

Somatic frameshift mutation in PIK3CA causes CLOVES syndrome by provoking PI3K/AKT/mTOR pathway
por: Yan, Wei, et al.
Publicado: (2021)

Mutations in PIK3CA sensitize breast cancer cells to physiologic levels of aspirin
por: Turturro, Sanja B., et al.
Publicado: (2016)

Aspirin sensitivity of PIK3CA-mutated Colorectal Cancer: potential mechanisms revisited
por: Hall, Daniella C. N., et al.
Publicado: (2022)

Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer
por: Wang, Dong, et al.
Publicado: (2016)

Surgical management for isolated macrodactyly in an adult PIK3CA mutant
por: Jacobs, C.J., et al.
Publicado: (2020)

Mutations in PI3K/AKT pathway genes and amplifications of PIK3CA are associated with patterns of recurrence in gastric cancers
por: Fang, Wen-Liang, et al.
Publicado: (2015)

Carcinogenesis of PIK3CA
por: German, Sidra, et al.
Publicado: (2013)

Phenotypic and genetic spectrum of isolated macrodactyly: somatic mosaicism of PIK3CA and AKT1 oncogenic variants
por: Tian, Wen, et al.
Publicado: (2020)

Lanthanum Chloride Causes Neurotoxicity in Rats by Upregulating miR-124 Expression and Targeting PIK3CA to Regulate the PI3K/Akt Signaling Pathway
por: Zheng, Linlin, et al.
Publicado: (2020)

Alterations of INPP4B, PIK3CA and pAkt of the PI3K pathway are associated with squamous cell carcinoma of the lung
por: Stjernström, Annika, et al.
Publicado: (2014)

PIK3CA copy-number gain and inhibitors of the PI3K/AKT/mTOR pathway in triple-negative breast cancer
por: Amato, Ottavia, et al.
Publicado: (2023)

Which Is the Most Appropriate PI3K Inhibitor for Breast Cancer Patients with or without PIK3CA Status Mutant? A Systematic Review and Network Meta-Analysis
por: Wang, Shu, et al.
Publicado: (2020)

Erzhi Pill(®) Protected Experimental Liver Injury Against Apoptosis via the PI3K/Akt/Raptor/Rictor Pathway
por: Zhao, Hai-Mei, et al.
Publicado: (2018)

Deactivation of Glutaminolysis Sensitizes PIK3CA-Mutated Colorectal Cancer Cells to Aspirin-Induced Growth Inhibition
por: Boku, Shogen, et al.
Publicado: (2020)

Mutant PIK3CA Induces EMT in a Cell Type Specific Manner
por: Bhagirath, Divya, et al.
Publicado: (2016)

Response of Brain Metastases From PIK3CA-Mutant Breast Cancer to Alpelisib
por: Batalini, Felipe, et al.
Publicado: (2020)

PIK3CA mutation in a case of CTNNB1-mutant sinonasal glomangiopericytoma
por: Hong, Christopher S., et al.
Publicado: (2022)

Mutant PIK3CA controls DUSP1-dependent ERK 1/2 activity to confer response to AKT target therapy
por: Sathe, A, et al.
Publicado: (2014)

PIK3CA in Colorectal Cancer
por: Cathomas, Gieri
Publicado: (2014)

Inhibitors of STAT3, β‐catenin, and IGF‐1R sensitize mouse PIK3CA‐mutant breast cancer to PI3K inhibitors
por: Merino, Vanessa F., et al.
Publicado: (2017)

De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes
por: Rivière, Jean-Baptiste, et al.
Publicado: (2012)

Molecular and Functional Characterization of Three Different Postzygotic Mutations in PIK3CA-Related Overgrowth Spectrum (PROS) Patients: Effects on PI3K/AKT/mTOR Signaling and Sensitivity to PIK3 Inhibitors
por: Loconte, Daria C., et al.
Publicado: (2015)

Nuclear translocation of p85β promotes tumorigenesis of PIK3CA helical domain mutant cancer
por: Hao, Yujun, et al.
Publicado: (2022)

PIK3CA copy number aberration and activation of the PI3K-AKT-mTOR pathway in varied disease states of penile cancer
por: Adimonye, Anthony, et al.
Publicado: (2018)

PIK3CA-mediated PI3-kinase signalling is essential for HPV-induced transformation in vitro
por: Henken, Florianne E, et al.
Publicado: (2011)

PIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitors
por: Payne, S N, et al.
Publicado: (2015)

Prevalence and Prognostic Role of PIK3CA/AKT1 Mutations in Chinese Breast Cancer Patients
por: Deng, Ling, et al.
Publicado: (2019)

Pilot study of sirolimus in patients with PIK3CA mutant/amplified refractory solid cancer
por: Jung, Ki Sun, et al.
Publicado: (2017)

miR-10a increases the cisplatin resistance of lung adenocarcinoma circulating tumor cells via targeting PIK3CA in the PI3K/Akt pathway
por: Huang, Tonghai, et al.
Publicado: (2020)

PIK3CA mutations are associated with increased tumor aggressiveness and Akt activation in gastric cancer
por: Kim, Ji-Won, et al.
Publicado: (2017)

Mutations of PIK3CA in gastric adenocarcinoma
por: Li, Vivian Sze Wing, et al.
Publicado: (2005)

Mutations in PIK3CA are infrequent in neuroblastoma
por: Dam, Vincent, et al.
Publicado: (2006)

PIK3CA-mutations in breast cancer
por: Reinhardt, Kristin, et al.
Publicado: (2022)

PIK3CA mutation inhibition in hormone receptor-positive breast cancer: time has come
por: De Mattos-Arruda, Leticia
Publicado: (2020)

Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells
por: Fujimoto, Yumi, et al.
Publicado: (2020)

Subcellular localization of FOXO3a as a potential biomarker of response to combined treatment with inhibitors of PI3K and autophagy in PIK3CA-mutant cancer cells
por: Kim, Hyun-Jung, et al.
Publicado: (2016)

PIK3CA mutation confers resistance to chemotherapy in triple-negative breast cancer by inhibiting apoptosis and activating the PI3K/AKT/mTOR signaling pathway
por: Hu, Huayu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_iclsjcdljc4epp43g5ilkc6vnl